This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Classification

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Rhinosinusitis is generally classified according to the duration into:

  • acute rhinosinusitis (ARS) - if duration of symptoms is less than 12 weeks
  • chronic rhinosinusitis (CRS) - if lasting more than 12 weeks (with or without acute exacerbations) (1)

Acute rhinosinusitis can be further divided into

  • acute viral rhinosinusitis (common cold) - duration of symptoms of less than 10 days
  • acute post-viral rhinosinusitis - defined by an increase in symptoms after 5 days or persistent symptoms after 10 days with less than 12 weeks duration.
  • acute bacterial rhinosinusitis—defined by the presence of at least three symptoms or signs of
    • discoloured discharge (with unilateral predominance) and purulent secretions
    • severe local pain (with unilateral predominance)
    • fever (>38°C)
    • elevated erythrocyte sedimentation rate or C reactive protein
    • ‘double sickening’ (i.e. a deterioration after an initial milder phase of illness) (1)
  • in recurrent acute sinusitis
    • there are four or more episodes of acute bacterial rhinosinusitis per year without signs or symptoms of sinusitis between episodes
    • each episode should meet the diagnostic criteria for acute bacterial sinusitis

Reference:

  1. Fokkens WJ et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012;23:3 p

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.